5th World Congress on Cancer Therapy
Chamow & Associates Inc., USA
Title: Molecular engineering of Fc fusion proteins to tailor effector function to clinical indication
Biography: Steven Chamow
The potential therapeutic value of many proteins—including enzymes, receptors, cytokines and peptides—can be realized by fusing these proteins to the Fc region of human immunoglobulin G. Eff ector functions mediated by Fc can signifi cantly alter the biological activity of Fc fusion proteins. Th ese functions include antibody dependent cell-mediated cytotoxicity (ADCC), which occurs through binding of the Fc domain to Fc receptors (FcR) on immune cells, as well as complementmediated cytotoxicity (CDC), induced by binding to C1q. Notably, Fc eff ector functions can be modulated through choice of Fc subclass, mutagenesis, and modifi cation of oligosaccharides. Th e use of Fc engineering to tailor eff ector function to clinical indication in this drug class will be discussed.